Surrey Heartlands

Joint Formulary & PAD

Bezafibrate - Lipid modification

You are here : Home > Formulary Search > Bezafibrate - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Modified release tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :
Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.

Documentation

Guidelines (National)
NICE Clinical guideline [CG71] : Familial hypercholesterolaemia: identification and management
Evidence Review
NICE CG71 and CG181 Briefing paper for PCN - Feb 2017
Information
Rosuvastatin and fibrate update following clarification from NICE - Oct 2014

PAD Profile

ChemicalSubstance :
Bezafibrate
Indication :
Lipid modification
Group Name :
Keywords :
Fibrates, high cholesterol, raised cholesterol, lipid lowering, hyperlipidaemia, FH, raised triglycerides, familial hypercholesterolaemia, hypertriglyceridaemia, lipid regulating
Brand Names Include :
Bezalip Mono, Fibrazate
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Lipid modification
Supporting Documents :
3

Other Indications

Below are listed other indications that Bezafibrate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.

Committee Recommendations (1)

01 Mar 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends the use of fibrates for lipid modification as follows:

Familial hypercholesterolaemia - as per NICE CG71 (updated July 2016) in patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe. Patients should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For these patients, fibrates should be considered BLUE (no information sheet) on the traffic light system. Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Hypertriglyceridaemia - as a treatment option for patients with hypertriglyceridaemia (>10mmol/L).
BLUE traffic light status - Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Policy statements and further information below.